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The function of p53 is best understood in response to genotoxic stress, but increasing evidence suggests
that p53 also plays a key role in the regulation of metabolic homeostasis. p53 and its family members directly
influence various metabolic pathways, enabling cells to respond to metabolic stress. These functions are
likely to be important for restraining the development of cancer but could also have a profound effect on
the development of metabolic diseases, including diabetes. A better understanding of the metabolic func-
tions of p53 family members may aid in the identification of therapeutic targets and reveal novel uses for
p53-modulating drugs.
Open access under CC BY license.The transcription factor p53 is best known for its role as a
tumor suppressor, and a wealth of evidence underscores the
importance of p53 in inhibiting cancer development (Vousden
and Prives, 2009). Mice lacking p53 are prone to the develop-
ment of early-onset spontaneous tumors (Donehower et al.,
1992). In most human cancers, p53 function is lost (Hollstein
et al., 1991), whereas patients that inherit one mutant TP53
allele display an enormously increased cancer risk, a condition
known as Li-Fraumeni syndrome (Varley, 2003). As a key
component in the cellular response to stress, p53 is activated
by numerous intrinsic and extrinsic stress signals, including
genotoxic damage, oncogene activation, loss of normal cell
contacts, and nutrient or oxygen deprivation—many of which
may be encountered during malignant transformation (Horn
and Vousden, 2007). The outcome of the p53-mediated stress
response depends on cell type and context as well as the
extent, duration, and origin of the stress. Severe or sustained
stress accompanied by irreversible damage, such as extreme
genotoxic damage or the activation of oncogenes, results in
the induction of cell death or senescence. Such responses
effectively eliminate the affected cells, thus limiting the inap-
propriate accumulation of cells with heritable genomic damage
and inhibiting malignant development. On the other hand, mild
stress results in a subtler p53 response consistent with repair-
ing or preventing damage. In such cases, p53 may engage
antioxidant responses in order to decrease ROS levels or
participate in DNA damage repair processes while inducing
a transient cell-cycle arrest, thereby allowing cells to survive
safely until the damage has been resolved. Transient meta-
bolic stresses—such as fluctuations in oxygen or nutrient
availability—also trigger a more adaptive response, in which
p53 induces metabolic remodelling and promotes catabolism,
while coordinating a decrease in proliferation and cell growth
(Figure 1) (Jones et al., 2005; Scherz-Shouval et al., 2010;
Maddocks et al., 2013). These metabolic functions of p53
are emerging as important components of the p53 response
that not only aid in maintaining normal cellular homeostasis
but also contribute to the control of tumor development. The
mechanisms through which p53 is activated by metabolic
and other stress signals are complex and have been reviewedelsewhere (Kruse and Gu, 2009). Once activated, p53 primarily
exerts its functions by acting as a transcription factor,
regulating the expression of both genes and microRNAs
(miRNAs). p53 has also been reported to possess cytosolic
functions. For example, cytoplasmic p53 has been reported
to inhibit autophagy (Tasdemir et al., 2008; Morselli et al.,
2009; Maiuri et al., 2010), interact with Bcl2 family members
to promote apoptosis (reviewed in Green and Kroemer,
2009), promote necrosis by opening the mitochondrial perme-
ability transition pore (Vaseva et al., 2012), and regulate
glucose metabolism by binding to glucose-6-phosphate dehy-
drogenase (G6PDH) (Jiang et al., 2011). Hence, the outcome
of p53 activation is complicated, and cell-fate decisions
are mediated by transcription-dependent and -independent
responses that can vary according to the level and posttrans-
lational modifications of p53 and its interaction with other pro-
teins, including other transcription factors (we will return to this
theme later).
Alterations in metabolism are increasingly regarded as
essential for tumor progression, and many reports suggest
that tumor cells become dependent on this metabolic remod-
elling for their growth and survival (Vander Heiden et al., 2009;
Ward and Thompson, 2012). Given its central role as a tumor
suppressor, it is not surprising that p53 can regulate several
aspects of cellular metabolism and thereby counteract many
of the metabolic alterations associated with cancer develop-
ment (Figure 1). p53 interacts with mammalian target of
rapamycin (mTOR) and AMP-activated protein kinase
(AMPK), two master regulators of cellular metabolism, directly
influences many key pathways involved in carbohydrate and
lipid metabolism, and regulates autophagy and the oxidative
stress response. Recently, metabolic roles have also been
ascribed to the p53 family members p63 and p73, further
broadening the impact of the p53 family on cell metabolism.
In this review, we discuss how p53 and its family members
regulate cellular metabolism through mechanisms that are
not only crucial for restraining the development of cancer
but could also profoundly influence other aspects of health
and disease, including aging and the development of meta-
bolic disease.Cell Metabolism 18, November 5, 2013 ª2013 The Authors 617
Figure 1. Outline of the Interaction between
p53 Family Members and Metabolic
Pathways
p53 and its family members p63 and p73 have
been implicated in many aspects of cellular meta-
bolism, including AMPK and mTOR signalling,
carbohydrate and lipid metabolism, the regulation
of autophagy, and the maintenance of mitochon-
drial integrity and REDOX balance.
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The Interplay between p53 and the Cell’s Metabolic
Sensors
The mTOR protein is an important positive regulator of cell
growth and proliferation that can influence the development of
diabetes, aging, and cancer (Zoncu et al., 2011). mTOR forms
two multimeric protein complexes, each with distinct functions
(Laplante and Sabatini, 2009). ThemTORC1 complex (consisting
of mTOR, Deptor, mLST8 [GbL], PRAS40, and Raptor) has been
studied extensively. Its downstream effectors control cell growth
and energy metabolism by regulating protein translation and
synthesis, mitochondrial biogenesis, lipid synthesis, and auto-
phagy (Howell and Manning, 2011). The functions of mTORC2
(consisting of mTOR, Deptor, mLST8 [GbL], Rictor, Sin1, and
Protor-1) are less well defined but include the regulation of the
cytoskeleton (Jacinto et al., 2004) and cell survival (Berchtold
and Walther, 2009). mTORC1 is active in the presence of both
adequate growth conditions (the availability of nutrients, oxygen,
and energy) and mitogens that positively signal for cell division.
Conversely, mTORC1 is inhibited by the absence of nutrients
or adequate growth conditions and by cellular stresses, which
can introduce genomic damage during the process of cell divi-
sion (Sengupta et al., 2010). Consequently, a number of impor-
tant signaling pathways converge on and coregulate mTORC1
activity (Figure 2), including the IGF/AKT/PI3K growth-factor-
signaling pathway and the p53 stress-signaling pathway. The
presence of nutrients and energy can be sensed by mTORC1
via various mechanisms. For example, energetic stress signals
to mTORC1 via the cellular fuel sensor AMPK. The activation of
AMPK (in response to an increase in the AMP to ATP ratio)
exerts an inhibitory effect on mTORC1 (Hardie et al., 2012) and
coordinates activities that allow cells to adapt to metabolic
stress. mTORC1 can also be activated in an amino-acid-depen-618 Cell Metabolism 18, November 5, 2013 ª2013 The Authorsdent manner. The presence of amino
acids stimulates the recruitment of
mTORC1 to the late endosomal and lyso-
somal compartments, which enables
mTORC1 to interact with sensors of
growth factor signaling (Zoncu et al.,
2011). By integrating amino acid sensing
with growth factor signaling, this mecha-
nism ensures that mTORC1 is only acti-
vated in the presence of both.
Given the influence of mTORC1
signaling, it is unsurprising that there are
multiple points of crosstalk with the p53
pathway, providing a reciprocal network
that is integral to cellular homeostasis
(Figure 2). p53 is activated in responseto stress, so it generally exerts an inhibitory effect upstream on
mTORC1 in order to shut down cell growth, cell division, and en-
ergy consumption under adverse conditions. p53 promotes the
expression of sestrins, which can activate AMPK (Budanov
and Karin, 2008), and thereby inhibit mTORC1 (Feng et al.,
2005). Other transcriptional targets of p53 that can negatively
regulate mTORC1 include AMPKb, TSC2, IGF-BP3, PTEN, and
Plk2, all of which are induced by genotoxic stress (Feng et al.,
2007; Matthew et al., 2009). Nongenotoxic p53 activation by nut-
lin-3a has also been shown to lead to mTOR inhibition via AMPK
activation (Drakos et al., 2009). Although nongenotoxic activa-
tion of p53 initially induces a cell-cycle arrest, the ability of p53
to inhibit mTOR in parallel is important in determining the even-
tual outcome of the p53 response. Cells that sustain mTOR
activity (such as through the deletion of TSC2) progress to irre-
versible senescence, a process named geroconversion,
whereas cells in which mTOR is inhibited (for example, through
p53 activation or under hypoxia) ultimately achieve a reversible
quiescent state (Korotchkina et al., 2010; Leontieva et al.,
2012). The intriguing suggestion here is that, whereas p53 pro-
motes quiescence, it suppresses geroconversion and senes-
cence (by inhibiting mTOR), which may contribute to tumor
suppression by preventing the induction of senescence-associ-
ated cancer-promoting responses (Blagosklonny, 2012). The
fact that AMPK can act both upstream and downstream of p53
adds another level of complexity to the p53-mTORC1-AMPK
signaling pathways. As described above, during genotoxic
stress and nongenotoxic activation of p53, AMPK can be acti-
vated downstream of p53 to inhibit mTORC1. However, during
energetic stress, AMPK acts upstream of p53, and the inhibition
of mTORC1 (by AMPK) occurs in concert with the AMPK-depen-
dent activation of p53 via serine-15 phosphorylation (Imamura
et al., 2001; Jones et al., 2005). This signal establishes a
Sestrins
Figure 2. Outline of the Crosstalk between p53 Family Members and the mTORC1 Pathway
p53 and p63 act upstream of mTORC1 and inhibit mTORC1 activity via multiple transcriptional targets. p53, p63, and p73 can all be modulated by the AMPK/
mTORC1 pathway (indicated in red and blue, respectively) and link mTORC1 signalling to multiple downstream effects, including, but not limited to, cell-cycle
control (via p53), autophagy (via p73), and differentiation (via p63).
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when cellular energy supplies are inadequate to support the
considerable demands of cell division, resulting in a transient
cell-cycle arrest. Furthermore, in hepatocellular carcinoma cells,
AMPK has been shown to exert an inhibitory effect on the p53
deacetylase Sirt1, thereby enhancing p53 acetylation and acti-
vation (Lee et al., 2012a). These studies suggest that AMPK
can activate p53 via various mechanisms. However, AMPK has
also been shown to activate Sirt1 and enhance the deacetylation
of Sirt1 targets in skeletal muscle cells (Canto´ et al., 2009), indi-
cating that the ability of AMPK to activate p53 via this route may
be tissue- and context-dependent.
Cellular homeostasis necessitates reciprocal and flexible
signaling between the mTOR and p53 pathways in order to bal-
ance adequate stress response with the requirement for growth
and proliferation (Feng and Levine, 2010). Indeed, like AMPK,
mTORC1 not only acts downstream of p53 but can also influence
p53 activity. For example, survival signaling through the Notch1
receptor, constitutive active forms of which have oncogenic
activity, activates mTORC1 via PI3K and AKT, resulting in the
inhibition of p53 activity by eIF4E, a translation initiation factordownstream of mTORC1 (Mungamuri et al., 2006). Conversely,
constitutive mTORC1 activation has been shown to activate
p53 by enhancing p53 translation (Lee et al., 2007) and inducing
the expression of alternative reading frame (ARF), a small protein
that inhibits MDM2, thus stabilizing p53 in response to oncogene
activation (Miceli et al., 2012). This suggests that abnormal
signaling through mTOR (a sign of malignant transformation) ac-
tivates p53 (Feng and Levine, 2010). Interestingly, AKT-induced
senescence occurs via mTORC1-dependent regulation of p53
translation and stabilization of p53 protein (Astle et al., 2012),
further supporting the notion that oncogenic signaling can acti-
vate p53 via mTOR. When a more restrained p53 response is
required (for example, in response to energetic stress), a feed-
back mechanism involving both AMPK and mTOR may aid in
mounting a transient and self-limiting p53 response. p53 acti-
vation by 5-Aminoimidazole-4-carboxamide ribonucleotide
(AICAR), an activator of AMPK, has been shown to be attenuated
by the inhibition of mTORC1, suggesting that a self-limiting feed-
back loop exists whereby AMPK activation simultaneously trig-
gers rapid p53 activation (via serine-15 phosphorylation) and
inhibition of mTOR, which eventually shuts down p53 translationCell Metabolism 18, November 5, 2013 ª2013 The Authors 619
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pretedwith caution, given that AICAR is an intermediate in nucle-
otide synthesis, the imbalance of which has been shown to
activate p53 (Linke et al., 1996). During some forms of metabolic
stress, the mTOR and p53 pathways may also operate indepen-
dently (Maddocks et al., 2013). Therefore, it is vital to view and
interpret the interplay between p53 and mTOR with careful
consideration for the specific context and tissue type.
The Regulation of Central Carbon Metabolism by p53
Glucose is a major carbon source for mammalian cells. Once it is
taken up by the cell, glucose is broken down to pyruvate in the
cytosol, a process known as glycolysis, which yields a limited
amount of ATP. Inmost normal (quiescent) cells, pyruvate is sub-
sequently fed into the mitochondrial tricarboxylic acid (TCA)
cycle in order to generate NADH and FADH2, which, in turn,
can be used for further ATP production via the highly efficient
process of oxidative phosphorylation (OXPHOS). However, the
majority of cancer cells display alterations in glucosemetabolism
(Ward and Thompson, 2012). Often, glycolysis is the preferred
pathway for producing energy, even under normal aerobic con-
ditions, and pyruvate is converted primarily to lactate. This shift
from mitochondrial respiration to aerobic glycolysis is known as
the Warburg effect, and this effect is thought to help satisfy the
altered metabolic needs of tumor cells. Their high rate of prolifer-
ation requires not only increased amounts of energy but also the
rapid production of building blocks necessary for growth and the
control of oxidative stress for maximal survival during growth
(Beaconsfield and Reading, 1964; Boros et al., 1998). Intermedi-
ates from glycolysis can serve as precursors for de novo amino
acid, lipid, and nucleotide synthesis and to generate reducing
agents that are crucial for maintaining the cellular redox state.
For example, an important secondary pathway that branches
from glycolysis is the pentose phosphate pathway (PPP), which
uses glucose-6-phosphate in reactions that ultimately produce
both NADPH and ribose-5-phosphate (R5P). NADPH is an
essential reducing agent in many biosynthetic reactions,
including de novo lipid synthesis, and helps to protect against
oxidative stress by regenerating reduced glutathione (GSH).
R5P is a critical component in the de novo synthesis of nucleo-
tides and nucleic acids. The role of the PPP is particularly evident
in cells or tissues that undergo proliferation, such as cancer
tissues (Beaconsfield et al., 1965; Wamelink et al., 2008; for
review see Tong et al., 2009) but also, for example, in regenerat-
ing liver tissues (Beaconsfield et al., 1965; Ledda-Columbano
et al., 1985). Furthermore, the importance of the PPP in cancer
is highlighted in various drug resistance studies that showed
that drug-resistant cancer cells often have an elevated PPP
activity in comparison to drug-sensitive cells (Gessner et al.,
1990; Fanciulli et al., 1993; Ferretti et al., 1993; McBrayer
et al., 2012); therefore, the inhibition of the PPP can often inhibit
tumor growth (Boros et al., 1997; Ramos-Montoya et al., 2006;
McBrayer et al., 2012). Increased expression of some PPP
enzymes, such as transketolase, has been suggested to be an
indicator for poorer cancer patient survival (Langbein et al.,
2006; McBrayer et al., 2012). Further down the glycolytic
pathway, glyceraldehyde-3-phosphate is an essential building
block for the production of triacylglycerols and phospholipids,
whereas 3-phosphoglycerate (3-PG) can be diverted to the
serine synthesis pathway in order to contribute to the production620 Cell Metabolism 18, November 5, 2013 ª2013 The Authorsof nucleotides as well as various nonessential amino acids,
which can also serve as substrates for GSH and phospholipid
synthesis.
p53 regulates both glycolysis and oxidative phosphorylation
and also modulates PPP activity (Figure 3). True to its role as a
tumor suppressor, p53 has been described to counteract the
Warburg effect by dampening aerobic glycolysis and promoting
oxidative phosphorylation through multiple mechanisms. Phos-
phofructose kinase 1 (PFK1), which catalyzes the third step of
the glycolytic pathway, is allosterically regulated by various
metabolites in the glucose metabolism pathways. Metabolites
such as ATP, citrate, and lactate, which indicate an adequate
supply of energy, directly inhibit PFK1, whereas PFK1 can be
activated by AMP and fructose-2,6-bisphosphate (F2,6BP).
p53 plays a critical role in this pathway by inducing the expres-
sion of TP53-induced glycolysis and apoptosis regulator
(TIGAR), which acts as a phosphatase that degrades F2,6BP
and thereby decreases the activity of PFK1. Hence, p53, via
TIGAR, lowers the glycolytic rate and would be predicted to pro-
mote the diversion of glycolytic intermediates into the PPP (Li
and Jogl, 2009; Bensaad et al., 2006). Other glycolytic enzymes
are also inhibited by p53 (Figure 3). In fibroblasts, protein levels
of phosphoglycerate mutase (PGAM), which catalyzes the con-
version of 3-PG to 2-PG, are downregulated by p53 (Kondoh
et al., 2005). p53 also negatively regulates the expression of
pyruvate dehydrogenase kinase 2 (PDK2), which inactivates
the pyruvate dehydrogenase complex (PDC), a protein that con-
verts pyruvate to acetyl-CoA. Hence, p53 activates PDC,
thereby favoring the production of acetyl-CoA at the expense
of lactate production (Contractor and Harris, 2012). In addition
to regulating glycolytic enzymes, p53 decreases intracellular
glucose levels by inhibiting glucose uptake. The expression of
the glucose transporters GLUT1 and GLUT4 is directly downre-
gulated by p53 (Schwartzenberg-Bar-Yoseph et al., 2004),
whereas p53 can also modulate the NF-kB pathway in order
to regulate glycolytic flux (Kawauchi et al., 2008b). Although
p53 enhances the DNA-binding activity of NF-kB, it also sup-
presses its transcriptional activity by inhibiting the activity of
IKKb (Kawauchi et al., 2008a, 2009). The net result of these
opposing p53 activities appears to be the inhibition of NF-kB ac-
tivity, which results in decreased GLUT3 expression (Kawauchi
et al., 2008b). Furthermore, the repression of monocarboxylate
transporter 1 (MCT1) expression by p53 prevents the efflux of
lactate under hypoxic conditions, which also dampens glyco-
lytic rates (Boidot et al., 2012). However, some of the described
activities of p53 seem to enhance rather than inhibit glycolysis.
For example, the promoters of both PGAM and hexokinase II
(HKII, which catalyzes the first step of glycolysis) contain p53-
responsive elements (Mathupala et al., 1997; Ruiz-Lozano
et al., 1999). The exact mechanisms underlying these apparently
opposing p53 activities are largely unknown. To some extent,
the regulation of the glycolytic pathway by p53 is likely to be
tissue- and context-dependent (Vousden and Ryan, 2009; Mad-
docks and Vousden, 2011). Indeed, a muscle-specific isoform of
PGAM is transcriptionally activated by p53 in cardiocytes (Ruiz-
Lozano et al., 1999), which is in contrast to the p53-dependent
destabilization of PGAM protein in fibroblasts (Kondoh et al.,
2005). Opposing p53 responses have also been reported in
the p53-dependent regulation of the PPP. The simultaneous
CoA
NFkB
Mieap
Malate
Figure 3. Outline of the Regulation of Central Carbohydrate Metabolism by p53
p53 generally dampens aerobic glycolysis (blue) and promotesmitochondrial respiration (green) throughmultiplemechanisms, although it can both positively and
negatively modulate PPP activity.
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expression of TIGAR) would lead to an increased flux into the
PPP. In contrast, p53 was recently described to inhibit the diver-
sion of glycolytic intermediates into the PPP by binding and
inhibiting G6PDH, the enzyme that catalyzes the first and rate-
limiting step of the PPP. These seemingly contradictory roles
of p53 in regulating the PPP most likely reflect, at least in part,
the differential p53 response to different types of stress. Oxida-
tive stress necessitates the upregulation of PPP activity in order
to increase NADPH production and support the antioxidant
response, and TIGAR has indeed been shown to be critical in
protection against oxidative stress (Bensaad et al., 2006), meta-
bolic stress (Bensaad et al., 2009; Wanka et al., 2012), and
hypoxia (Cheung et al., 2012). TIGAR-deficient mice are more
sensitive to acute intestinal injuries, and the growth defects of
TIGAR-null cells can be rescued by ROS scavengers and nucle-
otides (Cheung et al., 2013). On the other hand, by downregulat-ing PPP activity in developing cancer cells, p53 may counteract
the production of the building blocks that are critical for growth
and proliferation and thereby hinder tumor development.
The restriction of glycolytic flux by p53 is paralleled by the abil-
ity of p53 to drive OXPHOS and help maintain mitochondrial
integrity (Figure 3). p53 has been described to regulate mito-
chondrial DNA copy number and mitochondrial mass (Lebedeva
et al., 2009; Kulawiec et al., 2009) via the induction of p53R2
expression (p53-controlled ribonucleotide reductase) (Kulawiec
et al., 2009; Bourdon et al., 2007). p53 regulates mitochondrial
quality control by inducing the repair or removal of damaged
mitochondria (mitophagy) through the induction of mitochon-
dria-eating protein (Mieap) (Kitamura et al., 2011). Furthermore,
synthesis of cytochrome c oxidase 2 (SCO2)—a key component
involved in OXPHOS required for the assembly of the cyto-
chrome c oxidase (COX) complex (complex IV in the mitochon-
drial electron transport chain (ETC) and the major site of oxygenCell Metabolism 18, November 5, 2013 ª2013 The Authors 621
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Figure 4. Outline of the Regulation of Lipid Metabolism by p53
p53 generally functions as a negative regulator of lipid synthesis by enhancing
fatty acid oxidation (red) and inhibiting fatty acid synthesis (blue) through
multiple mechanisms.
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by p53 (Matoba et al., 2006), as is subunit I of the COX complex
(Okamura et al., 1999). A third target that is transcriptionally acti-
vated by p53 in this context is apoptosis-inducing factor (AIF)
(Stambolsky et al., 2006), which is essential for the maintenance
of mitochondrial complex I (Vahsen et al., 2004). In addition to
promoting OXPHOS, other activities of p53 may increase the
TCA cycle rate. For example, p53 transcriptionally activates
glutaminase 2 (GLS2) (Hu et al., 2010; Suzuki et al., 2010), amito-
chondrial glutaminase that catalyzes the hydrolysis of glutamine
to glutamate, which can fuel the TCA cycle after its conversion to
a-ketoglutarate. p53 also transcriptionally represses the expres-
sion of malic enzymes ME1 and ME2, which recycle malate to
pyruvate, and p53 could thereby inhibit the utilization of TCA
cycle intermediates into biosynthetic pathways and NADPH
production (Jiang et al., 2013). In contrast to its role in main-
taining mitochondrial health under mild stress or nonstressed
conditions, p53 represses PGC-1a and PGC-1b, transcriptional
cofactors that aremaster regulators ofmitochondrial biogenesis,
under conditions of extreme stress, such as telomere shortening.
This leads to mitochondrial dysfunction, which—along with in-
duction of the classical p53 functions (senescence, apoptosis,
and cell-cycle arrest)—has been proposed to contribute to aging
(Sahin et al., 2011).
p53 as a Regulator of Lipid Metabolism
Lipid metabolism is a highly regulated and synchronized pro-
cess. Fatty acids can be used by cells as an energy source or
a means of storing surplus energy. Fatty acid oxidation (FAO)
takes place in the mitochondria and breaks down fatty acids
into two-carbon units in order to yield acetyl-CoA, NADH, and
FADH2, which can be channelled directly to the TCA cycle and622 Cell Metabolism 18, November 5, 2013 ª2013 The Authorselectron transport chain to produce ATP (Figure 4). Fatty acid
synthesis takes place in the cytosol and uses two-carbon units
to form a gradually elongating carbon chain in a process that
requires ATP and NADPH. Thus, to avoid futile cycling, these
reciprocal pathways are separated into different cellular com-
partments and regulatory mechanisms at various levels ensure
that they do not occur simultaneously. De novo fatty acid synthe-
sis occurs mainly in a limited number of tissues—i.e., adipose
tissue, the liver, and lactating mammary glands. Fatty acids are
transported to cells throughout the body through the circulation
in the form of lipoprotein particles, which are made up of newly
synthesized fatty acids as well as dietary fatty acids, and are ex-
ported from adipose, liver, or gut tissues. When supply is higher
than demand, fatty acids can be stored in liver and fat tissue in
lipid droplets, mainly in the form of triglycerides. Another impor-
tant branch of lipid metabolism is the mevalonate pathway,
through which the two-carbon acetyl groups are utilized to syn-
thesize cholesterol. Whereas adult differentiated cells obtain
lipids mainly from the diet, highly proliferative cells such as em-
bryonic stem cells and cancer cells display high rates of de novo
fatty acid synthesis for generating building blocks for new mem-
branes as the cells divide and for steroid hormones that enhance
cell growth (Swinnen et al., 2006; Santos and Schulze, 2012).
Multiple tumor types display elevated levels of cholesterol or lipid
droplets. Expression of key enzymes in the fatty acid synthesis
pathway, such as fatty acid synthase (FASN), acetyl CoA carbox-
ylase (ACC), and ATP citrate lyase (ACLY), was shown to be
reactivated in various tumors and contribute to cell transforma-
tion and tumorigenesis (Swinnen et al., 2006). Additionally, the
PI3K-AKT and mTOR pathways, which are commonly activated
in cancer cells (Yang et al., 2002; Santos and Schulze, 2012), are
known to enhance lipid synthesis. Finally, under hypoxic condi-
tions that are expected to occur in solid tumors, FAO is inhibited
because NADH and FADH2 cannot be oxidized and, thus, such
conditions shift the balance toward lipid synthesis and accumu-
lation (Santos and Schulze, 2012).
p53 plays a crucial role in lipid metabolism, participating in
both normal and pathological conditions. True to its role as a
tumor suppressor, p53 generally functions as a negative regu-
lator of lipid synthesis by activating fatty acid oxidation and
inhibiting fatty acid synthesis (Figure 4). Mouse embryonic fibro-
blasts that can be induced to differentiate into adipocytes pro-
vide a well-described model for the study of lipogenic cells. In
this model system, the role of p53 as a negative regulator of adi-
pogenesis is apparent—activated p53 inhibits adipocyte differ-
entiation (Hallenborg et al., 2009), and p53 knockout enhances
lipid accumulation (Molchadsky et al., 2008; Wang et al., 2013).
The mechanisms by which p53 exerts an antilipogenic effect
on cells seem complex and are probably multifaceted. Lipid
metabolism is controlled by the mTOR pathway (Figure 2) and
is tightly linked to glycolysis and the PPP, which supply the build-
ing blocks (acetyl-CoA and NADPH) needed for lipid synthesis
(Figure 3). Thus, modulation of these pathways by p53 contrib-
utes to an altered lipogenic status of the cell. p53 has also
been demonstrated to directly affect the expression of proteins
involved in lipid metabolism (Figure 4) (an extensive review of
lipid-metabolism-related genes regulated by p53 can be found
in Goldstein and Rotter, 2012). For example, p53 induces the
expression of carnitine acetyltransferases (such as CPT1C),
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the mitochondria for FAO (Zaugg et al., 2011). p53 has also been
demonstrated to regulate key transcription factors responsible
for the expression of genes involved in determining cellular lipo-
genic status, such as sterol regulatory element-binding protein 1
(SREBP1)—a key transcription factor for genes involved in fatty
acid synthesis. p53 suppresses the expression of the SREBP1c
isoform in mouse adipose tissue, contributing to the repression
of FASN and ACLY (Yahagi et al., 2003). After glucose starvation,
p53 induces guanidinoacetate methyltransferase (GAMT), an
enzyme involved in creatine synthesis, which facilitates in-
creased FAO through mechanisms that are still unknown (Ide
et al., 2009). Under similar conditions, p53 activation by ROS in-
duces lipin1 (a negative regulation of SREBP activity) in C2C12
myoblasts, which also results in enhanced FAO, whereas knock-
down of p53 attenuates the increase in FAO in response to
glucose starvation (Assaily et al., 2011). Inhibition of mTORC1
has been shown to promote the nuclear entry of lipin1, a process
that could further contribute to the p53-mediated repression of
SREBP activity (Peterson et al., 2011). Although the conse-
quences of p53-mediated promotion of FAO may allow cells to
adapt and survive when glucose is no longer available, the ATP
generated in response to GAMT activation by p53 has also
been shown to support apoptosis (Ide et al., 2009).
p53 and the Regulation of ROS
The regulation by p53 of carbohydrate and lipid metabolism is
tightly linked to another important function of p53: the regulation
of ROS. In its role as a ‘‘guardian of the cell,’’ p53 can eliminate
the deleterious effects of oxidative insult either by limiting ROS
damage in cells that can be salvaged or by using ROS to elimi-
nate cells damaged beyond repair. Hence, if the insult is tran-
sient and repairable, then p53 can activate a suite of antioxidant
responses, many of which are linked to carbohydrate or lipid
metabolism. For example, the activation of the PPP via TIGAR
produces NADPH that can reduce glutathione, an important
cellular antioxidant. Interestingly, a recent study showed that
p53 can also directly promote GSH synthesis at the expense of
nucleotide synthesis after serine deprivation, and, thereby, it
actively controls ROS levels under conditions ofmetabolic stress
(Maddocks et al., 2013). Mitochondria are a major source of
ROS, especially when they are damaged. The downregulation
of AIF, for example, leads to enhanced levels of ROS that are
due to defective mitochondrial function (Klein et al., 2002).
Hence, by maintaining mitochondrial integrity, basal p53 activity
may also limit ROS production. In addition, p53 transcriptionally
activates antioxidant genes to offer protection against damage.
Examples of p53-induced anti-ROSproteins includemembers of
the sestrin family (Budanov and Karin, 2008), aldehyde dehydro-
genase (ALDH4) (Yoon et al., 2004), and TP53INP1 (Cano et al.,
2009). p53 can also act as an inhibitor to repress the expression
of pro-oxidant genes such as nitric oxide synthase (NOS2)
(Ambs et al., 1998) and cyclooxygenase 2 (COX2) (Subbara-
maiah et al., 1999). On the other hand, if the damage is irrepa-
rable, p53 may evoke a pro-oxidant state, which will ensure
the demise of the damaged cell (see Zhuang et al., 2012, for
an extensive review of pro-oxidant genes activated by p53).
For example, p53 has been shown to activate genes such as
those encoding proline oxidase (PIG6/POX) and ferredoxin
reductase (Liu and Chen, 2002; Rivera and Maxwell, 2005) andto inhibit proteins (directly or by transcriptional repression)
involved in the antioxidant response, such as G6PDH, malic en-
zymes, and manganese superoxide dismutase (Zhao et al.,
2005; Jiang et al., 2011; Jiang et al., 2013). Although the general
effect of pro-oxidant functions of p53 is related to enhanced cell
death, the consequences of p53-mediated control of ROS are
complicated by the requirement of ROS for proliferative as well
as cell-death signaling. In this context, the ability of p53 to acti-
vate theNox2 complex for the production of ROS has been asso-
ciated with redox-sensitive signaling that mediates proliferation
and survival (Italiano et al., 2012). How different stresses result
in different p53-dependent ROS responses is not exactly known,
but the interaction of p53 with other proteins and transcription
factors is most likely one of the factors that mediates this pro-
cess. Posttranslational modifications on p53 (such as phosphor-
ylation or acetylation) or simply the amount of p53 (low basal
levels of p53 or higher amounts of activated p53) may influence
the nature of these interactions. For example, basal p53 levels
have been described to increase catalase activity and decrease
ROS under physiological conditions, whereas p53 that is acti-
vated by genotoxic stress switches to inhibit catalase activity,
leading to a pro-oxidant state (Kang et al., 2013). Also, the inter-
action between p53 and Nrf2 (a master regulator of the oxidative
stress response), which we will discuss in more detail later, is
likely to be important in determining the outcome of the p53-
dependent regulation of ROS.
The Roles of p53 in Regulating Autophagy
Autophagy (here referring to macroautophagy), which literally
translates as ‘‘self-eating,’’ is an important cellular catabolic pro-
cess carried out in the cytoplasm. Autophagy is characterized by
the formation of double-membraned autophagosomes around
cytoplasmic components that have been targeted for degrada-
tion. Once enclosed around their cargo, autophagosomes fuse
with lysosomes, forming autolysosomes in which the delivered
contents are then catabolized (Rubinsztein et al., 2012). Auto-
phagy fulfils two basic functions important to normal cellular
homeostasis: the removal of aged or dysfunctional organelles
and proteins and the release of nutrients liberated from
the degraded macromolecules. Autophagy is upregulated in
response to cellular stresses, including nutrient deprivation
(Mordier et al., 2000) and oxidative stress (Kiffin et al., 2004).
Although it was initially thought that autophagy was responsible
for a form of cell death, this hypothesis has been revised in light
of a large body of evidence supporting autophagy as a prosur-
vival mechanism (Levine and Kroemer, 2009). Autophagy is
involved in a wide range of pathologies, including metabolic,
neurodegenerative, and inflammatory diseases aswell as cancer
(Rubinsztein et al., 2012). It has been proposed that, although
basal levels of autophagy have a tumor suppressor function,
stress-responsive autophagy could promote the survival of
tumor cells faced with metabolic stress (Morselli et al., 2009;
Scherz-Shouval et al., 2010).
The relationship between p53 and autophagy is complex,
given that p53 can both promote and inhibit autophagy in a
context-dependent manner (Maiuri et al., 2010; Morselli et al.,
2009; Maddocks and Vousden, 2011). This ability to suppress
or enhance autophagymay allow p53 to provide themost appro-
priate cell-survival strategy during nutrient starvation (Scherz-
Shouval et al., 2010); in mouse embryonic fibroblasts with lowCell Metabolism 18, November 5, 2013 ª2013 The Authors 623
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ing starvation. Conversely, in HCT116 cells, in which the basal
autophagic flux is high, p53 inhibits autophagy by downregulat-
ing LC3 mRNA at the posttranscriptional level in response to
starvation in order to promote limited but sustainable levels of
autophagy over time (Scherz-Shouval et al., 2010). It has also
been proposed that the intracellular location of p53 activity
dictates these functions. Nuclear (activated) p53 most likely ac-
tivates autophagy (via transcriptional activation of autophagy-
inducing proteins), whereas basal levels of cytoplasmic p53
directly inhibit autophagy (Maiuri et al., 2010; Morselli et al.,
2009; Tasdemir et al., 2008).
The activation of autophagy by (nuclear) p53 is well estab-
lished and can occur through a variety of mechanisms. The
mTORC1 pathway is a major inhibitory regulator of autophagy.
Hence, by negatively regulating mTORC1 (Figure 2), p53 acti-
vates autophagy. Furthermore, several p53 targets activate
autophagy independently of mTOR. DRAM-1 is activated by
p53 and encodes multiple isoforms that regulate autophagy
(Crighton et al., 2006; Mah et al., 2012). The proapoptotic p53
target PUMA has been shown to induce selective mitochondrial
autophagy (mitophagy), which is dependent on Bax (Yee et al.,
2009). Recently, ISG20L1 has been identified as a transcriptional
target of all three p53 family members that upregulates
autophagy in response to genotoxic stress (Eby et al., 2010).
The tumor suppressor protein ARF has been shown to activate
autophagy by p53-dependent and -independent means (Abida
and Gu, 2008; Reef and Kimchi, 2008). Recently, the p53-indu-
cable gene Ei24 was found to be an essential component of
the basal autophagy pathway in neurons and hepatocytes and
to regulate autophagy under nonstressed conditions (Zhao
et al., 2012), suggesting that p53 may play a homeostatic role
in promoting autophagy. Interestingly, a reciprocal regulation
of p53 by at least one ATG protein (autophagy-related gene, a
family of proteins that play critical roles in the autophagy pro-
cess) has recently been described. In addition to its role in the
lipidation of LC3 (ATG8) (Tanida et al., 2012), ATG7 promotes
p53-dependent transcription of p21CDKN1A (encoding p21, an
inhibitor of cyclin-dependent kinases), thereby promoting cell-
cycle arrest and survival in response to nutrient starvation (Lee
et al., 2012b).
The role of cytoplasmic p53 in the regulation of autophagy was
established by suppressing p53 expression in colon cancer
(HCT116) cells. Surprisingly, this resulted in the upregulation of
autophagy, whereas the reintroduction of p53 repressed auto-
phagy (Tasdemir et al., 2008). In similar experiments, the expres-
sion of cancer-relevant p53mutants in p53/HCT116 cells also
inhibited autophagy, the mutants showing the highest cyto-
plasmic localization having the greatest effect (Morselli et al.,
2008). It seems that the ability of p53 to suppress autophagy de-
pends (at least in part) on complex formation with components
and regulators of the autophagic machinery in either the cyto-
plasm or the nucleus. One example of this is HMGB1, a chro-
matin-binding factor with nuclear and cytoplasmic functions
that interacts with p53 (Livesey et al., 2012). Under normal con-
ditions, HMGB1 and p53 are localized to the nucleus in com-
plexes that prevent the release of either protein to the cytoplasm.
Loss of p53 causes the translocation of HMGB1 to the cytosol,
where it interacts with ATG6 (Beclin1) to promote autophagy.624 Cell Metabolism 18, November 5, 2013 ª2013 The AuthorsThe reintroduction of p53 suppresses this process and, there-
fore, inhibits autophagy (Livesey et al., 2012).
p53’s Interaction with Other Transcription Factors
Clearly, the identification of an ever-increasing number of func-
tions for p53 provokes the important question of how the final
response of the cell is determined. Many of the examples dis-
cussed above indicate that the particular outcome of the activa-
tion of p53 depends on the level of the insult. This may influence
the activity of p53 itself as well as that of other proteins or tran-
scriptional factors that ultimately determine the fate of the cell.
p53 has clear relationships with other transcription factors that
are known to be critical in the response to metabolic stress,
most notably PGC, SREBP, and Nrf2. PGC-1a is a critical regu-
lator of glucose, lipid, and energy metabolism, whose functions
include the regulation of mitochondrial biogenesis and the
expression of antioxidants. Under conditions of mild metabolic
stress, p53 has been shown to increase PGC-1a expression,
resulting in the induction of an antioxidant response (Aquilano
et al., 2013). Moreover, a recent study demonstrated that
PGC-1amodulates the transcriptional activity of p53 under con-
ditions of glucose starvation to boost its metabolic function. This
results in the recruitment of p53 to proarrest and metabolic
genes, including p21 and TIGAR, leading to antioxidant
responses, cell-cycle arrest, and survival. On the other hand,
prolonged starvation resulted in the degradation of PGC-1a,
leading to a proapoptotic p53 response (Sen et al., 2011). p53
also interacts with SREBPs, critical regulators of the genes that
control lipid and sterol synthesis. Although wild-type (WT) p53
can repress SREBP1c-dependent gene expression in mouse
adipose tissue (Figure 4) (Yahagi et al., 2003), tumor-associated
mutant p53 has been shown to bind and transcriptionally acti-
vate SREBP2 in breast cancer cells, resulting in the induction
of the mevalonate pathway (Freed-Pastor et al., 2012). Although
the effect of SREBPs on p53-dependent gene expression has
not yet been explored, it is possible that p53 and SREBP will
mutually regulate each other. Finally, recent studies describe a
complicated connection between p53 and Nrf2. Pharmacolog-
ical activation of Nrf2 has been shown to suppress tumor pro-
gression. However, constitutively activated Nrf2 also contributes
to drug resistance and tumor cell survival (Sporn and Liby, 2012),
an effect that may be mediated by protection against ROS and
an increase in anabolic pathways, including the PPP, purine syn-
thesis pathways, and glutaminolysis (Mitsuishi et al., 2012). p53
has been shown to both enhance and repress Nrf2 activity; low
basal p53 levels enhance Nrf2 protein levels to promote survival,
and high stress levels result in the inhibition of Nrf2 by p53 and
the induction of ROS and apoptosis (Chen et al., 2012). Similarly,
p53 levels have been shown to be both positively and negatively
regulated by Nrf2, and it has been suggested that Nrf2 and p53
synergize in enhancing the antioxidant response (Rotblat et al.,
2012). The mechanisms by which p53 can both enhance and
repress Nrf2 are still largely unknown. The enhancement of
Nrf2 protein levels by p53 is dependent on p21 (a transcriptional
target of p53) (Chen et al., 2012), which has been reported to sta-
bilize and activate Nrf2 by binding to KEAP1, thereby inhibiting
the proteasomal degradation of Nrf2 (Chen et al., 2009). It has
also been shown that p53 can directly interact with certain pro-
moter elements of Nrf2 target genes, resulting in the transcrip-
tional repression of these genes (Faraonio et al., 2006), but
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derlying mechanisms of these seemingly opposing actions of
p53. Although the complicated interactions between p53 and
metabolic transcription factors such as PGC, SREBP, and Nrf2
are still poorly understood, they may prove to be key to under-
standing the different outcomes to p53 activation in response
to different types of stress. It is also tempting to speculate that
the interaction with these transcription factors may help ensure
that the extent and desired outcomes of the p53 response are
coordinated with the extent of metabolic remodelling induced
by p53. This may ensure channeling of the available cellular
ATP stores to where they are needed most during different
conditions. For example, if the energy-demanding process of
DNA damage repair is desirable, then the required energy may
be generated via the simultaneous p53-dependent remodelling
of energy-generating pathways. Another example may be the
simultaneous activation of both cell death and autophagy by
p53 during severe stress. Given that autophagy is essentially a
prosurvival mechanism, it remains puzzling why two seemingly
opposed processes should be concomitantly active. A possible
alternative explanation may be that autophagy accompanies
p53-induced apoptosis to ensure an adequate supply of meta-
bolic precursors (i.e., for energy production), without which this
active, energy-dependent process could stall.
The p53 Family: p63 and p73 in Metabolism
p53 belongs to a family of transcription factors that also includes
p63 and p73, functional homologs of p53 that show high sequen-
tial and structural similarity. Both the Tp63 and Tp73 genes are
transcribed from two distinct promoters, resulting in either full-
length proteins that retain a full transactivation (TA) domain
(TAp63 and TAp73) or N-terminally truncated isoforms (DNp63
andDNp73) that lack part of this domain but still retain some abil-
ity to activate transcription. In addition, alternative RNA splicing
results in different C termini for both p63 and p73 isoforms,
termed a-ε and a-h, respectively. TAp63 and TAp73 can supple-
ment p53 function by transactivating p53 target genes, resulting
in cell-cycle arrest and apoptotic cell death, although p63 and
p73 also have distinct transcriptional targets. In contrast,
DNp63 and DNp73 generally have antiapoptotic functions and
have been shown to act as dominant negatives for inhibiting
the function of p53 family members. However, DN isoforms
also activate specific sets of target genes and function indepen-
dently of other p53 family isoforms. Despite these similarities and
overlap in activity, p63 and p73 each have functions that are
strikingly different from those of p53, and both proteins play crit-
ical roles in development (reviewed in Allocati et al., 2012). For
example, Tp63/ mice show defects in the development of
epithelial tissues as well as truncated limbs, and p63 also
appears to be essential for the maintenance of stem cells. In
humans, mutations in p63 cause ectodermal dysplasias, syn-
dromes characterized by defects of ectodermal structures
(such as hair and teeth). Unlike p63, p73 is essential for proper
neural development, and p73 knockout mice display develop-
mental defects in the CNS. Analysis of selective TAp73 or
DNp73 knockdown suggested that DNp73 isoforms are neces-
sary for neuronal survival, whereas TAp73 is required for the
long-term maintenance and differentiation of neuronal stem
cells. Both p63 and p73 are important for germ cell maintenance.
p63 controls the quality of the female germline by eliminatingdamaged oocytes, whereas p73 maintains genomic stability of
the oocyte pool.
A number of recent studies have shown that both p63 and p73
function in the regulation of different aspects of metabolism. Like
p53, p63 interacts with both AMPK and the mTOR pathway
(Figure 2), and the deregulation of p63 has been shown to affect
lipid metabolism (Sabbisetti et al., 2009; Su et al., 2012). Activa-
tion of mTORC1 induces TAp63 and DNp63 expression, which
form part of an mTOR/p63/Notch signaling cascade that can in-
fluence cell differentiation (Ma et al., 2010). TAp63 positively reg-
ulates the transcription of Sirt1, AMPKa2, and LKB1 and thereby
coordinates fat and glucose metabolism. Loss of TAp63 results
in defects in lipid utilization, fatty acid synthesis, and FAO, and
mice lacking TAp63 consequently display insulin resistance as
well as symptoms of obesity, type 2 diabetes, and premature
aging (Su et al., 2012). DNp63a has been shown to transcription-
ally activate FASN in both transformed and immortalized epithe-
lial cells, and the maintenance of fatty acid synthesis contributes
to the prosurvival activity of p63 during development (Sabbisetti
et al., 2009). In addition, isoforms of p63 may play a role in medi-
ating the metabolic response to drug treatment. For example,
TAp63g levels are elevated in response to treatment with metfor-
min (a drug widely used to treat type 2 diabetes that reduces
insulin resistance via mechanisms that include the inhibition of
mitochondrial respiratory chain complex I, which ultimately
results in the activation of AMPKa), and TAp63g was crucial for
the metformin-induced activation of AMPKa (Su et al., 2012).
Recent work with squamous cell carcinoma cells suggests
a significant role for DNp63a as a multifaceted regulator of
stress-induced autophagy. Cisplatin treatment leads to phos-
phorylation of DNp63a by ataxia telangiectasia mutated (ATM;
a protein involved in the response to DNA damage that can
also activate p53), which resulted in phospho-DNp63a depen-
dent expression of several genes in the ATG family (Huang
et al., 2012b). Furthermore, multiple phospho-DNp63a respon-
sive miRNAs were found to modulate the activity of ATG
proteins, suggesting that DNp63-induced autophagy could
contribute to cisplatin resistance. Interestingly, DNp63a and
phospho-DNp63a induced different sets of metabolic target
genes upon cisplatin treatment, including genes involved in
carbohydrate and lipid metabolism (Huang et al., 2012a).
Like p53, p73 is a major transcriptional regulator of autophagy
(Crighton et al., 2007); but, whereas p53 influences autophagy by
acting upstream of mTORC1, p73 expression is negatively regu-
lated downstream of mTORC1 (Figure 2) (Rosenbluth et al.,
2008). Hence, p73 is activated when mTOR signaling is inhibited
and targets multiple autophagosome- and lysosome-associated
genes to promote autophagy (Rosenbluth et al., 2008; Rose-
nbluth and Pietenpol, 2009). Given that the activation of auto-
phagy is a major feature of mTOR inhibition, this places p73 as
an important player in the response to cellular stress and makes
it possible that signals initiated by p53 eventually direct p73 ac-
tivity. Another difference between p53 and p73 in the regulation
of autophagy is the role of DRAM-1. Although p73 (like p53) posi-
tively regulates DRAM-1, p73-induced autophagy is indepen-
dent of DRAM-1 activation and is not associated with cell death
(Crighton et al., 2007). Interestingly, DNp73 can inhibit p53- and
p73-dependent stress-induced autophagy, but not starvation-
induced autophagy (Crighton et al., 2007), suggesting theCell Metabolism 18, November 5, 2013 ª2013 The Authors 625
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regulated by p73. The inhibition of p73 bymTORC1 also controls
several genes involved in insulin response (Rosenbluth et al.,
2008; Rosenbluth and Pietenpol, 2009) as well as genes and
miRNAs involved in mesenchymal differentiation and tumorigen-
esis (Rosenbluth et al., 2011). In addition, p73 is negatively
regulated by AMPK via direct interaction with AMPKa, which
selectively represses the p73 transcriptional program (Lee
et al., 2009). Finally, TAp73 has been implicated in the regulation
of mitochondrial respiration. Cytochrome c oxidase subunit 4 is
a TAp73 target, and the depletion of TAp73 resulted in a
decrease in the activity of mitochondrial complex IV, paralleled
with decreased oxygen consumption and ATP production and
increased levels of ROS. Consequently, TAp73/ mice showed
signs of premature aging associated with increased oxidative
damage and senescence (Rufini et al., 2012).
Physiological Relevance of the Metabolic Functions
of the P53 Family
Cancer
The canonical functions of p53—the induction of cell-cycle
arrest, senescence, and apoptotic cell death—have long been
regarded as the key mechanisms by which p53 inhibits tumor
development, but this view is being increasingly challenged.
Mice lacking PUMA, a p53 target gene that is critical in mediating
p53’s apoptotic activity in many tissues (Yu and Zhang, 2008),
fail to develop early-onset spontaneous tumors (Michalak
et al., 2008). Similarly, p5325,26, a p53 mutant that retains the
ability to induce senescence, but not p53-mediated cell-cycle
arrest and apoptosis, still inhibited KrasG12D-induced lung
carcinogenesis (Brady et al., 2011). Although the p53 target
gene p21CDKN1A is critical for inducing p53-dependent senes-
cence and cell-cycle arrest, mice lacking p21 are not prone to
develop early-onset tumors (Choudhury et al., 2007). Even
mice that express p533KR, a mutant that has lost p53-dependent
cell-cycle arrest, apoptosis, and senescence, are protected from
early-onset tumorigenesis (Li et al., 2012). Intriguingly, p533KR
retains some of the metabolic functions of WT p53; i.e., it can
regulate metabolic target genes such as GLS2, GLUT3, and
TIGAR, resulting in decreased ROS levels and the suppression
of glucose uptake and glycolytic flux. This suggests that the
metabolic functions of p53 may be central to p53’s role as a
tumor suppressor, especially when its canonical functions are
compromised. A recent study revealing that the regulation of
TCA cycle enzymes by p53 strongly induced senescence further
underscored the interdependence of the canonical and meta-
bolic functions of p53 in tumor suppression (Jiang et al., 2013).
So, how do the metabolic functions of p53 contribute to tumor
suppression? Some help to prevent the accumulation of herita-
ble genomic damage and, therefore, hinder tumor development.
Examples of such functions are the coordination of cell growth
and proliferation via mTOR and AMPK, the ability to lower ROS
levels and restore the redox balance, and the activation of auto-
phagy to remove aged or dysfunctional organelles (Figure 1). In
addition, p53 directly opposes many aspects of the metabolic
transformation that seem crucial for malignant transformation
and cancer progression. For example, p53 directly counteracts
the Warburg effect by dampening glycolysis and promoting
oxidative phosphorylation. By inhibiting PPP activity, opposing626 Cell Metabolism 18, November 5, 2013 ª2013 The Authorsfatty acid synthesis, and inducing FAO, p53 opposes anabolism
and prevents cells from adopting a more lipogenic status
(Figure 1). Hence, regulating the metabolic state of the cell
may serve as an independent mechanism by which p53 can
restrain tumor development. This multilayer protection afforded
by p53 can be regarded as additional insurance for preventing
tumor development, but some of p53’s prosurvival roles are
not always easily reconciled with tumor suppression. The ability
of p53 to lower ROS levels, for example, might help established
tumor cells to survive oxidative stress. Similarly, the role of p53 in
limiting glycolysis also promotes the diversion of glycolytic inter-
mediates into anabolic pathways such as the PPP. Also, p53-
induced activation of autophagy could be beneficial for tumor
growth under conditions of metabolic stress. Normally, these
prosurvival p53 activities would be tightly controlled in order to
avoid the activation of an improper response, but, clearly, hijack-
ing the metabolic functions of p53 under conditions of sustained
stress—in which repair or recovery is not possible—could help
rather than hinder tumor development. Indeed, the presence of
p53 has been shown to protect tumor cells frommetabolic stress
induced by glucose or serine starvation (Jones et al., 2005; Mad-
docks et al., 2013). The regulation of autophagy by p53 has been
shown to promote tumor cell survival under conditions of chronic
nutrient deprivation (Scherz-Shouval et al., 2010), and p53
protects cancer cells against treatment with metformin, an inhib-
itor of mitochondrial respiratory chain complex I (Buzzai et al.,
2007), although a recent study did not show enhanced sensitivity
of p53/ tumors to the mitochondrial inhibitor phenformin
(Shackelford et al., 2013). Clearly, these results are complicated
by the observation that p63 can also participate in the response
to metformin (Su et al., 2012). The ability of p53 to allow cells to
withstand stress and damage also extends to human cancer,
where the retention of WT p53 can predict a good response in
some cancers but is also associated with poor prognosis and
poor response to therapy in breast tumors (Bertheau et al.,
2008). Several p53 target proteins may also play dual roles.
The regulation of FAO by p53 through CPT1C expression pre-
sumably helps to buffer brain cells from nutrient stress (San-
chez-Macedo et al., 2013). However, the overexpression of
CPT1C (independent of p53) contributes to the survival of cancer
cells under glucose deprivation or hypoxia (Zaugg et al., 2011).
Similarly, the p53 target protein TIGAR is critical in the response
to stress, and decreased TIGAR levels have been associated
with increased migration, proliferation, and tumorigenicity in
cells depleted of citrate synthase (Lin et al., 2012). On the other
hand, TIGAR promotes the activity of the PPP and HK2 under
hypoxia (Cheung et al., 2012), activities that would be predicted
to assist tumorigenesis, and also protects against radiotherapy
induced DNA damage and senescence (Pen˜a-Rico et al.,
2011). Interestingly, the activity of PFKFB4, another enzyme
with phosphatase function similar to TIGAR, has recently been
shown to be necessary for the survival of prostate cancer cells
(Ros et al., 2012). Furthermore, the role of TIGAR in maintaining
tumor cell survival is highlighted by the fact that some tumor
types have elevated levels of TIGAR expression (Wanka et al.,
2012; Won et al., 2012), and the inhibition of certain therapeutic
targets is associated with a decrease of TIGAR expression.
For example, the inhibition of c-MET, a protein that is often
associated with poor patient survival, leads to a decrease in
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et al., 2011).
Both p63 and p73 have been implicated in tumor suppression
and protection from metastasis. Interestingly, metabolic func-
tions that show similarities to those exhibited by p53 are now
beginning to be unraveled for both these proteins. TAp63 influ-
ences glucose and lipid metabolism (Su et al., 2012), whereas
TAp73 has been implicated in autophagy, the control of ROS,
and the maintenance of mitochondrial complex IV (Rufini et al.,
2012). However, it remains to be determined whether the meta-
bolic functions of p63 and p73 contribute to tumor suppression
(or even tumor promotion) and how they do it. The discovery
that p53 family members regulate metabolism may also have
important implications for tumors that express (oncogenic)
mutant forms of p53, as is the case in an estimated half of all
human cancers. Both p63 and p73 can be bound by these p53
mutants (Gaiddon et al., 2001), which thereby functionally
deplete cells of all p53 family members. Thus, mutations in p53
not only lead to a loss of WT p53 function but also to gains of
function that are associated with the inhibition of p63 and p73
function, such as the promotion of invasion and metastasis
(Muller et al., 2009). Interestingly, mutant p53 also displays
such a gain of function in the context of metabolism. The inhibi-
tion of autophagy by cancer-relevant p53mutants (Morselli et al.,
2008) may be mediated through the interaction of mutant p53
with p73 (Zawacka-Pankau et al., 2010). However, mutant p53
can also control metabolism independently of exerting control
over p63 or p73. In the context of lipid metabolism, mutant p53
has been found to activate genes from the mevalonate pathway
in breast cancer cells (Freed-Pastor et al., 2012). As mentioned
above, this is achieved by binding to the transcriptional activator
of cholesterol biosynthesis genes SREBP2, which does not
interact with WT p53. These studies suggest that mutant p53
proteins may exert still unknown effects on cellular metabolism,
either independently or via the inactivation of p53 family mem-
bers, which may promote tumor development.
Metabolic Syndrome
Metabolic syndrome is a major health problem in industrialized
societies. Characterized by obesity, insulin resistance, glucose
intolerance, and diabetes, metabolic syndrome is associated
with an increased risk of cardiovascular disease and cancer.
Furthermore, the connection between diabetes and cancer is
highlighted by several studies that show that the antidiabetic
drug metformin can potentially have anticancer effects. In
diabetics, metformin use is associated with a reduced risk of
cancer and lower cancer mortality as well as with increased
complete response rates to neoadjuvant chemotherapy in breast
cancer (reviewed in Jalving et al., 2010).
Given that p53 plays an important role in the regulation of lipid
metabolism, it may not be surprising that p53 has been demon-
strated to be involved in systemic conditions related to lipid
metabolism, such type 2 diabetes and obesity (Yahagi et al.,
2003; Minamino et al., 2009; Wang et al., 2013). However, the
role of p53 in metabolic disease is complex. As a form of meta-
bolic stress, the effect of nutrient excess on the p53 pathway has
received less attention than nutrient depletion. Given the pres-
ence of excess glucose and fat in the so-called ‘‘western diet’’
and the propensity of diabetes to induce high levels of circulating
glucose, this topic warrants attention. p53 has been shown tocontribute to the pathogenesis of metabolic disease in mouse
models, especially under conditions of nutrient excess. High lipid
levels (i.e., obesity) increase oxidative stress levels and lead
to p53 induction. This activation of p53 may help to curtail lipid
accumulation by enhancing lipid catabolism (Goldstein and
Rotter, 2012) but could also result in insulin resistance and dia-
betes (Minamino et al., 2009). Indeed, adipocytes from obese
mice display elevated levels of p53 (Yahagi et al., 2003), and liver
p53 levels are induced in mouse models of hepatic steatosis
(fatty liver disease) associated with obesity (Yahagi et al., 2004)
and chronic alcohol consumption (Derdak et al., 2011). In these
models, knockdown or chemical inhibition of p53 ameliorates
disease. For example, p53 deficiency improves insulin sensitivity
in genetically obese mice (Minamino et al., 2009). In models of
steatosis, the inhibition of p53 diminished triglyceride accumula-
tion and promoted FAO in the liver (Derdak et al., 2013). Similarly,
high glucose levels inhibit AMPK activity and increase ROS
generation. This leads to the upregulation of Nox4 and the acti-
vation of p53-induced apoptosis in glomerular epithelial cells
(podocytes), the loss of which may contribute to albuminuria
and diabetic kidney disease. The reactivation of AMPK by AICAR
in this context leads to a reduction in Nox4 levels, resulting in a
suppression of p53 (Eid et al., 2010). Likewise, metformin-
induced AMPK and Sirt1 activation has been shown to lower
p53 protein levels in hepatoma cells exposed to high glucose,
whereas the overexpression of p53 in this context attenuated
the effects of metformin on AMPK activation (Nelson et al.,
2012). These studies illustrate the complexity and context
dependence of the p53 response, given that, under condition
of low glucose, AMPK activation induces p53.
However, other studies suggest that p53 can protect from the
development of obesity, diabetes, and liver steatosis. In male
mice on a high-fat diet, the loss of p53 resulted in a substantial
increase in liver lipid accumulation and bodymass in comparison
to WT animals (Wang et al., 2013). Moreover, the inability to
properly activate p53 has been shown to contribute to glucose
intolerance. Mice carrying a p53mutant that cannot be activated
by ATM through phosphorylation develop insulin resistance and
glucose intolerance, which are associated with a decreased anti-
oxidant function (Armata et al., 2010). Mice that ectopically
express D40p53, a p53 mutant that lacks part of the transactiva-
tion domain, also exhibit glucose intolerance, hypoinsulinemia,
and defects in b cell mass and proliferation, suggesting that
p53 plays a role in the regulation of b cell proliferation (Hinault
et al., 2011). Conversely, super-p53 mice, which express an
additional copy of normally regulated WT p53, have been found
to display improved glucose tolerance (Franck et al., 2013).
Another way in which p53 may be involved in the protection
from diabetes is by protecting preadipocytes from ROS. Adipo-
cytes are important in the maintenance of metabolic homeosta-
sis and protection from lipotoxicity. p53 has been suggested to
help adipocytes handle the effects of lipid and cholesterol
overload, thereby maintaining adipocyte viability (Bazuine
et al., 2009).
These contradictory results suggest that the outcome of p53
activation is tissue specific and most likely depends on the
type of stress. Another possibility is that basal levels of p53
help in maintaining lipid homeostasis (Goldstein and Rotter,
2012) and protect from metabolic disease, whereas theCell Metabolism 18, November 5, 2013 ª2013 The Authors 627
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bolic stress (such as nutrient excess or obesity) may ultimately
contribute to disease pathogenesis. Recently, depletion of
TAp63 has been shown to result in obesity and symptoms of
type 2 diabetes in both aging mice and mice consuming a
high-fat diet. The protective effects of TAp63 are thought to
be mediated via the transcriptional activation of Sirt1, AMPKa2,
and LKB1 (Su et al., 2012). On the other hand, knockdown of
TAp73 resulted in an increase in insulin sensitivity and protection
from glucose intolerance in mice on a high-fat diet, possibly
because of the positive effects of ROS on insulin signaling (Rufini
et al., 2012). Once again, these observations underscore the
complex role of the p53 family during the development of
metabolic syndrome.
Aging
Aging is characterized by functional decline and is closely linked
to the development of cancer, neurodegeneration, and meta-
bolic disease. p53 is thought to play an important but complex
role in the regulation of aging and longevity, and contradictory
studies have shown that p53 expression can both promote
and inhibit premature aging. Initial studies showed that mice
carrying one truncated p53 mutant allele that exhibits increased
p53 activity (p53+/m mice) had a shortened lifespan (Tyner et al.,
2002). Similarly, mice expressing a naturally occurring 44 kD
truncated isoform of p53 displayed a reduced longevity and
symptoms of early aging (Maier et al., 2004). However, more
recent studies suggest that these early aging phenotypes are
caused by abnormal and chronic enhancement of p53 activity,
whereas normally regulated p53 could increase longevity (Hinkal
et al., 2009; Matheu et al., 2007). Indeed, neither super-p53 mice
nor mice in which p53 is stabilized as a result of low MDM2
activity displayed early-aging phenotypes (Garcı´a-Cao et al.,
2002; Mendrysa et al., 2006). Moreover, super-p53 mice that
also carried an additional p19ARF allele display a hyperrespon-
sive p53 pathway, which results in increased longevity (Matheu
et al., 2007). The underlying mechanisms by which p53 regulates
aging are not completely understood. The ability of p53 to com-
bat oxidative stress by inducing antioxidant responses and
maintaining mitochondrial integrity could promote longevity
and protect from early aging (Maddocks and Vousden, 2011).
Similarly, the ability of p53 to negatively regulate the mTOR
and AKT signaling pathways could contribute to a longevity
phenotype, given that this would mimic the effects of caloric
restriction (Gudkov et al., 2011). In support of this hypothesis,
the inhibition of mTOR by p53 has been shown to switch the
ultimate outcome of the p53 response from irreversible senes-
cence to reversible quiescence, whereas the inhibition of
mTOR by rapamycin mimicked the suppression of senescence
by p53 (Korotchkina et al., 2010). Therefore, it has been hypoth-
esized that p53 regulates senescence (and thereby aging) via a
two-step mechanism (Gudkov et al., 2011) in which the activa-
tion of p53 by genotoxic or oncongenic stress leads to a cell-
cycle arrest, whereas the decision on the irreversibility of this
arrest depends on the inhibition of mTOR. Conversely, it has
been proposed that, upon DNA damage (for example, by telo-
mere dysfunction), p53 promotes aging through the repression
of PGC-1a and PGC-1b, resulting in mitochondrial dysfunction.
This sustains a feedforward cycle by increasing DNA damage
(for example, through increased ROS generation), followed by628 Cell Metabolism 18, November 5, 2013 ª2013 The Authorssustained p53 activation, additional mitochondrial compromise,
and so on, ultimately resulting in increased apoptosis, senes-
cence, and aging (Sahin and DePinho, 2012).
Both p53 family members have also been implicated in the
regulation of aging and longevity, albeit through different mech-
anisms. Selective depletion of TAp73 results in premature aging
associated with mitochondrial dysfunction (due to decreased
complex IV activity) and increased levels of ROS (Rufini et al.,
2012). Furthermore, both the selective knockout of TAp63
(Su et al., 2009) and the complete deletion of p63 (Keyes et al.,
2005) result in accelerated aging, suggesting a role for TAp63
in the regulation of aging. Although TAp63/ mice show some
of the same premature aging defects as TAp73/ mice, the
aging phenotype in TAp63/ mice is thought to be caused by
a hyperproliferation of stem cells (Su et al., 2009). Another
intriguing possibility is that the inhibition of p63 and p73 by
mutant p53 plays a role in the proaging phenotypes of p53+/m
mice (Flores and Lozano, 2012). However, additional work is
needed in order to elucidate the mechanisms by which the p53
family regulates aging and longevity.
Future Directions
The metabolic functions of p53 are emerging as critical not only
for tumor suppression but also for maintaining normal cellular
homeostasis. Nevertheless, many questions remain. Clearly,
different stress signals can activate different p53 responses,
as measured by transcriptional profiles, and several proteins
that contribute to the ability of p53 to promote adaptation to
metabolic stress are preferentially activated by p53 in response
to nutrient deprivation (Sen et al., 2011). However, little is known
about themolecular mechanisms that govern the outcome of the
p53 response. Although the induction of p53 after genotoxic
damage generally depends on the stabilization of p53, this
does not seem to be a universal requirement for the activation
of a metabolic p53 response. During serine starvation, for
example, recruitment of p53 to the p21 promoter and robust
induction of p21 expression are observed in response to
modest stabilization of p53 (Maddocks et al., 2013). Most likely,
posttranslational modifications of p53 during different types and
intensities of stress contribute to p53 target gene selection
(Vousden and Prives, 2009; Smeenk and Lohrum, 2010). How-
ever, as discussed above, to reach various end points (or cell-
fate decisions), much may depend on the interaction of p53
with critical transcription factors in the regulation of metabolism.
Future studies into the mechanisms that activate p53 and
mediate the p53 response under conditions of metabolic stress
will not only increase our understanding of the regulation of
metabolism by p53 but may also shine light on the complex
role of the metabolic functions of p53 in pathologies such as
cancer and diabetes. Finally, delineating how metabolism may
be regulated by the p53 family members p63 and p73 will also
be important for understanding the possible metabolic roles of
oncogenic mutant forms of p53. The extent to which p53 family
members interact with lipid and carbohydrate metabolism, cell
growth, and the process of autophagy is complicated and
context dependent. Additional insight into these relationships
will increase our understanding of how these interactions influ-
ence health and disease and, potentially, how they can be
manipulated for our benefit.
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